Literature DB >> 24868439

Surgical management of advanced non-small cell lung cancer.

Gonzalo Varela1, Pascal Alexandre Thomas1.   

Abstract

More than 75% of the cases of non-small cell lung cancer (NSCLC) are diagnosed in advanced stages (IIIA-IV). Although in these patients the role of surgery is unclear, complete tumor resection can be achieved in selected cases, with good long-term survival. In this review, current indications for surgery in advanced NSCLC are discussed. In stage IIIA (N2), surgery after induction chemotherapy seems to be the best option. The indication of induction chemotherapy plus radiotherapy is debatable due to potential postoperative complications but recently reported experiences have not shown a higher postoperative risk in patients after chemo and radiotherapy induction even if pneumonectomy is performed. In cases of unexpected N2 found during thoracotomy, lobectomy plus systematic nodal dissection is recommended mostly for patients with single station disease. In stage IIIB, surgery is only the choice for resectable T4N0-1 cases and should not be indicated in cases of N2 disease. Favorable outcomes are reported after extended resections to the spine and mediastinal structures. Thorough and individualized discussion of each stage IIIB case is encouraged in the context of a multidisciplinary team. For stage IV oligometastatic cases, surgery can still be included when planning multimodality treatment. Brain and adrenal gland are the two most common sites of oligometastases considered for local ablative therapy.

Entities:  

Keywords:  Non-small cell lung cancer (NSCLC); extended pulmonary resection; multimodality treatment; surgical therapy

Year:  2014        PMID: 24868439      PMCID: PMC4032956          DOI: 10.3978/j.issn.2072-1439.2014.04.34

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  53 in total

1.  Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

Authors:  J A Roth; E N Atkinson; F Fossella; R Komaki; M Bernadette Ryan; J B Putnam; J S Lee; H Dhingra; L De Caro; M Chasen; W K Hong
Journal:  Lung Cancer       Date:  1998-07       Impact factor: 5.705

2.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

3.  Surgical results for multiple primary lung cancers.

Authors:  F Rea; A Zuin; D Callegaro; L Bortolotti; G Guanella; F Sartori
Journal:  Eur J Cardiothorac Surg       Date:  2001-09       Impact factor: 4.191

Review 4.  Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer.

Authors:  Asad A Shah; Mark F Berry; Ching Tzao; Mihir Gandhi; Mathias Worni; Ricardo Pietrobon; Thomas A D'Amico
Journal:  Ann Thorac Surg       Date:  2012-06       Impact factor: 4.330

Review 5.  Surgery for early stage non-small cell lung cancer.

Authors:  R Manser; G Wright; D Hart; G Byrnes; D A Campbell
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

6.  Multi-institutional study of radiation therapy for isolated para-aortic lymph node recurrence in uterine cervical carcinoma: 84 subjects of a population of more than 5,000.

Authors:  Yuzuru Niibe; Masahiro Kenjo; Tomoko Kazumoto; Koichi Michimoto; Makoto Takayama; Chikako Yamauchi; Masaaki Kataoka; Kazunori Suzuki; Noriko Ii; Takashi Uno; Tsuyoshi Takanaka; Keiko Higuchi; Hideya Yamazaki; Sunao Tokumaru; Masahiko Oguchi; Kazushige Hayakawa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-01       Impact factor: 7.038

7.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

8.  Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer.

Authors:  Paul De Leyn; Christophe Dooms; Jaroslaw Kuzdzal; Didier Lardinois; Bernward Passlick; Ramon Rami-Porta; Akif Turna; Paul Van Schil; Frederico Venuta; David Waller; Walter Weder; Marcin Zielinski
Journal:  Eur J Cardiothorac Surg       Date:  2014-02-26       Impact factor: 4.191

Review 9.  Surgical treatments for multiple primary adenocarcinoma of the lung.

Authors:  Masao Nakata; Shigeki Sawada; Motohiro Yamashita; Hideyuki Saeki; Akira Kurita; Shigemitsu Takashima; Kazuo Tanemoto
Journal:  Ann Thorac Surg       Date:  2004-10       Impact factor: 4.330

10.  Survival and prognostic factors of surgically resected T4 non-small cell lung cancer.

Authors:  Toshihiro Osaki; Kenji Sugio; Takeshi Hanagiri; Mitsuhiro Takenoyama; Toshihiro Yamashita; Masakazu Sugaya; Manabu Yasuda; Kosei Yasumoto
Journal:  Ann Thorac Surg       Date:  2003-06       Impact factor: 4.330

View more
  14 in total

1.  Safety and feasibility of uniportal video-assisted thoracoscopic surgery for locally advanced non-small cell lung cancer.

Authors:  Junqiang Fan; Jie Yao; Qi Wang; Zhibo Chang
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

2.  Effect of rapamycin (RAPA) on the growth of lung cancer and its mechanism in mice with A549.

Authors:  Linmei Wang; Ruiling Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

3.  Clinical outcomes of cytoreductive surgery combined with intrapleural perfusion of hyperthermic chemotherapy in advanced lung adenocarcinoma with pleural dissemination.

Authors:  Eunjue Yi; Daejoong Kim; Sukki Cho; Kwhanmien Kim; Sanghoon Jheon
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

4.  Prognostic analysis of the bronchoplastic and broncho-arterioplastic lobectomy of non-small cell lung cancers-10-year experiences of 161 patients.

Authors:  Li-Lan Zhao; Fang-Yu Zhou; Chen-Yang Dai; Yi-Jiu Ren; Ge-Ning Jiang; Ke Fei; Chang Chen
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

Review 5.  Surgical approaches in patients with oligometastatic non-small cell lung cancer.

Authors:  Luca Bertolaccini; Alessandro Pardolesi; Sergio Nicola Forti Parri; Barbara Bonfanti; Jury Brandolini; Piergiorgio Solli
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

6.  Extended resections for the treatment of patients with T4 stage IIIA non-small cell lung cancer (NSCLC) (T4N0-1M0) with or without cardiopulmonary bypass: a 15-year two-center experience.

Authors:  Dimitrios Filippou; Athanasios Kleontas; Vasilios Tentzeris; Christos Emmanouilides; Stavros Tryfon; Sofia Baka; Ioanna Filippou; Kostas Papagiannopoulos
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

7.  Clinical investigation into the initial diagnosis and treatment of 1,168 lung cancer patients.

Authors:  Qian Shao; Jianbin Li; Fengxiang Li; Suzhen Wang; Wei Wang; Shanshan Liu; Yingjie Zhang
Journal:  Oncol Lett       Date:  2014-12-08       Impact factor: 2.967

8.  Incomplete radiofrequency ablation accelerates proliferation and angiogenesis of residual lung carcinomas via HSP70/HIF-1α.

Authors:  Jun Wan; Wei Wu; Yunlong Huang; Wei Ge; Shandong Liu
Journal:  Oncol Rep       Date:  2016-06-07       Impact factor: 3.906

9.  Local recurrence of small cell lung cancer following radiofrequency ablation is induced by HIF-1α expression in the transition zone.

Authors:  Jun Wan; Wei Wu; Renquan Zhang
Journal:  Oncol Rep       Date:  2015-12-31       Impact factor: 3.906

Review 10.  Locally advanced non-small cell lung cancer: the place of specialist thoracic surgery in the multidisciplinary team.

Authors:  Muteb Al Zaidi; Gavin M Wright
Journal:  Transl Lung Cancer Res       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.